1KJ Stock Overview
A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
10x Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.41 |
| 52 Week High | US$57.18 |
| 52 Week Low | US$17.72 |
| Beta | 1.87 |
| 11 Month Change | -11.11% |
| 3 Month Change | -47.50% |
| 1 Year Change | -64.76% |
| 33 Year Change | -88.83% |
| 5 Year Change | n/a |
| Change since IPO | -66.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1KJ | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 2.8% | -0.5% | 0.09% |
| 1Y | -64.8% | -14.4% | 3.1% |
Return vs Industry: 1KJ underperformed the German Life Sciences industry which returned -14.4% over the past year.
Return vs Market: 1KJ underperformed the German Market which returned 3% over the past year.
Price Volatility
| 1KJ volatility | |
|---|---|
| 1KJ Average Weekly Movement | 9.3% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1KJ's share price has been volatile over the past 3 months.
Volatility Over Time: 1KJ's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,259 | Serge Saxonov | www.10xgenomics.com |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell.
10x Genomics, Inc. Fundamentals Summary
| 1KJ fundamental statistics | |
|---|---|
| Market cap | €2.18b |
| Earnings (TTM) | -€246.96m |
| Revenue (TTM) | €584.42m |
3.8x
P/S Ratio-9.0x
P/E RatioIs 1KJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1KJ income statement (TTM) | |
|---|---|
| Revenue | US$625.45m |
| Cost of Revenue | US$221.31m |
| Gross Profit | US$404.14m |
| Other Expenses | US$668.44m |
| Earnings | -US$264.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.21 |
| Gross Margin | 64.62% |
| Net Profit Margin | -42.26% |
| Debt/Equity Ratio | 0% |
How did 1KJ perform over the long term?
See historical performance and comparison